Search

Your search keyword '"Angermann, Christiane E."' showing total 325 results

Search Constraints

Start Over You searched for: Author "Angermann, Christiane E." Remove constraint Author: "Angermann, Christiane E." Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
325 results on '"Angermann, Christiane E."'

Search Results

2. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study

3. Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry

5. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

7. Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post‐hoc analysis from EMPULSE.

8. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study

10. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial.

11. Prevalence of anti‐beta‐1 antibody 6 months after hospitalization for acute heart failure predicts adverse outcome

13. Hospitalization for acute heart failure during non‐working hours impacts on long‐term mortality: the REPORT‐HF registry

14. Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE

15. Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT‐HF

16. The Win Ratio Method in Heart Failure Trials: Lessons Learnt From Empulse

17. Hospitalization for acute heart failure during non-working hours impacts on long-term mortality: the REPORT-HF registry

18. Association of time-to-intravenous furosemide with mortality in acute heart failure : data from REPORT-HF

19. Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT-HF

20. Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of <scp>REPORT‐HF</scp>

21. Association of time‐to‐intravenous furosemide with mortality in acute heart failure: data from REPORT‐HF

22. Effects of remote haemodynamic‐guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the MEMS‐HF study

23. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

24. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial

25. Quality of life assessed six months after hospitalisation for acute heart failure: an analysis from REPORT‐HF (International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure)

26. Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring

27. Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the MEMS-HF study

28. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure:a multinational randomized trial

29. Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT-HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure)

30. Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction

31. Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension:insights from the MEMS-HF study

32. A global perspective of racial differences and outcomes in patients presenting with acute heart failure

33. Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry

34. Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring

35. Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring

38. Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT‐HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure)

39. Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction

40. Syncopes and clinical outcome in heart failure: results from prospective clinical study data in Germany

41. Sex-specific bimodal clustering of left ventricular ejection fraction in patients with acute heart failure

42. A global perspective of racial differences and outcomes in patients presenting with acute heart failure

43. EMPAGLIFLOZIN IN PATIENTS HOSPITALIZED FOR DE NOVO VERSUS DECOMPENSATED CHRONIC HEART FAILURE: INSIGHTS FROM THE EMPULSE TRIAL

44. Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT‐HF registry

45. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.

47. Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring

48. International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry

50. Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.

Catalog

Books, media, physical & digital resources